- Home
- RAVE vs MREO Comparison
RAVE vs MREO Comparison
Compare RAVE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAVE | MREO |
|---|---|---|
| Founded | 1958 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 50.3M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RAVE | MREO |
|---|---|---|
| Price | $3.04 | $0.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 18.9K | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 16.67 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $15,120,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $20.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.25 | $0.20 |
| 52 Week High | $3.75 | $2.37 |
Technical Indicators
Market Signals| Indicator | RAVE | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 41.21 |
| Support Level | $3.07 | $0.22 |
| Resistance Level | $3.43 | $0.35 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 39.65 | 23.45 |
Price Performance
Historical ComparisonAbout RAVE Rave Restaurant Group Inc.
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).